1. Home
  2. SAMG vs CING Comparison

SAMG vs CING Comparison

Compare SAMG & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silvercrest Asset Management Group Inc.

SAMG

Silvercrest Asset Management Group Inc.

HOLD

Current Price

$10.02

Market Cap

76.4M

Sector

Finance

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$4.75

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAMG
CING
Founded
2002
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.4M
64.5M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
SAMG
CING
Price
$10.02
$4.75
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
53.2K
146.4K
Earning Date
05-01-2026
05-08-2026
Dividend Yield
6.36%
N/A
EPS Growth
N/A
56.47
EPS
0.05
N/A
Revenue
$91,358,000.00
N/A
Revenue This Year
$8.99
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$203.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.57
$3.16
52 Week High
$16.88
$11.89

Technical Indicators

Market Signals
Indicator
SAMG
CING
Relative Strength Index (RSI) 48.00 N/A
Support Level $9.64 N/A
Resistance Level $11.61 N/A
Average True Range (ATR) 0.37 0.00
MACD 0.03 0.00
Stochastic Oscillator 43.48 0.00

Price Performance

Historical Comparison
SAMG
CING

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: